Patents Assigned to W. Alton Jones Cell Science Center
-
Patent number: 5846734Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: W. Alton Jones Cell Science CenterInventor: Ginette Serrero
-
Patent number: 5817769Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.Type: GrantFiled: June 7, 1995Date of Patent: October 6, 1998Assignee: W. Alton Jones Cell Science CenterInventor: Ginette Serrero
-
Patent number: 5723115Abstract: Epidermal growth factor (EGF), which can act as a potent inhibitor of adipocyte differentiation in vitro, affects adipose tissue differentiation in vivo and can suppress obesity. Methods are provided for inhibiting the differentiation of adipocyte precursor cells, and for treating or preventing obesity, which comprise administering an effective amount of a composition capable of binding to and activating the EGF receptor, preferably epidermal EGF or a functional derivative thereof, TGF.alpha., an antibody specific for the EGF receptor or an anti-idiotypic antibody specific for an idiotope on an antibody specific for EGF. Also provided is a method for determining the susceptibility of a subject to obesity or determining the presence of obesity associated with an abnormality in EGF or EGF receptor, which comprises measuring EGF in a body fluid or the amount or activity of EGF receptor protein or mRNA in adipocyte precursors.Type: GrantFiled: December 2, 1993Date of Patent: March 3, 1998Assignee: W. Alton Jones Cell Science Center, Inc.Inventor: Ginette Serrero
-
Patent number: 5541068Abstract: A mammalian adipocyte-specific polypeptide, termed p154, is expressed in high quantities in adipogenic cell lines after cell differentiation and is abundant in the fat pads of normal and genetically obese mammals. The murine and human polypeptide, DNA and RNA molecules coding therefor, methods for its preparation, and antibodies specific for the polypeptide are also disclosed. Methods for determining the susceptibility of a subject to obesity are based on measuring the levels of the adipocyte polypeptide in a biological fluid or tissue extract or by measuring mRNA encoding the polypeptide in cells of the subject. Methods of evaluating an anti-obesity drug comprise contacting the drug with an adipocyte in vitro and measuring the amount of the adipocyte polypeptide or mRNA produced by the adipocyte. Methods of treating a subject with obesity comprise administering the above antibody or blocking the expression of the p154 gene.Type: GrantFiled: November 22, 1993Date of Patent: July 30, 1996Assignee: W. Alton Jones Cell Science Center, inc.Inventor: Ginette Serrero
-
Patent number: 5459061Abstract: Hybridomas producing monoclonal antibodies that specifically bind to the human EGF receptor and compete with EGF for binding to the EGF receptor are described. The subject monoclonal antibodies bind to an epitope located between residues Ala-351 and Asp-364 of the EGF receptor, which is not denatured by boiling, treatment with detergent or treatment with a reducing agent.Type: GrantFiled: October 7, 1993Date of Patent: October 17, 1995Assignee: W. Alton Jones Cell Science Center, Inc.Inventors: J. Denry Sato, Dianging Wu, Lihua Wang
-
Patent number: 5449757Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.Type: GrantFiled: March 22, 1994Date of Patent: September 12, 1995Assignee: W. Alton Jones Cell Science CenterInventor: Ginette Serrero
-
Patent number: 5427926Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.Type: GrantFiled: August 16, 1994Date of Patent: June 27, 1995Assignee: W. Alton Jones Cell Science Center, Inc.Inventors: Vincenzo Buonassisi, Patricia C. Colburn
-
Patent number: 5356783Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.Type: GrantFiled: January 25, 1993Date of Patent: October 18, 1994Assignee: W. Alton Jones Cell Science Center, Inc.Inventors: Vincenzo Buonassisi, Patricia C. Colburn
-
Patent number: 5268295Abstract: A mammalian adipocyte-specific polypeptide, termed p154, is expressed in high quantities in adipogenic cell lines after cell differentiation and is abundant in the fat pads of normal and genetically obese mammals. The murine and human polypeptide, DNA and RNA molecules coding therefor, methods for its preparation, and antibodies specific for the polypeptide are also disclosed. Methods for determining the susceptibility of a subject to obesity are based on measuring the levels of the adipocyte polypeptide in a biological fluid or tissue extract or by measuring mRNA encoding the polypeptide in cells of the subject. Methods of evaluating an anti-obesity drug comprise contacting the drug with an adipocyte in vitro and measuring the amount of the adipocyte polypeptide or mRNA produced by the adipocyte. Methods of treating a subject with obesity comprise administering the above antibody or blocking the expression of the p154 gene.Type: GrantFiled: May 31, 1991Date of Patent: December 7, 1993Assignee: W. Alton Jones Cell Science Center, Inc.Inventor: Ginette Serrero
-
Patent number: 5219994Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.Type: GrantFiled: February 5, 1992Date of Patent: June 15, 1993Assignee: W. Alton Jones Cell Science Center, Inc.Inventors: Vincenzo Buonassisi, Patricia C. Colburn
-
Patent number: 5110737Abstract: Cholesterol auxotrophy of myeloma cells is used as the basis for selecting hybridomas. The outgrowth of nascent hybridomas in a cholesterol-free medium was 3- to 9-fold more efficient than that in HAT medium and resulted in 3- to 13-times as many antigen-reactive hybridoma cells. This method of hybridoma selection can be applied with any sterol-dependent parent cell line. The nutrient medium is also preferably free of Ham's F-12 nutrient mixture.Type: GrantFiled: July 31, 1989Date of Patent: May 5, 1992Assignee: W. Alton Jones Cell Science Center IncorporatedInventors: Yoshinari Myoken, Tetsuji Okamoto, J. Denry Sato